HOOKIPA Pharma Files 8-K

TL;DR

HOOKIPA Pharma filed a routine 8-K, no major news.

AI Summary

HOOKIPA Pharma Inc. filed an 8-K on January 29, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements for this form type.

Why It Matters

This filing indicates HOOKIPA Pharma Inc. is meeting its regulatory reporting obligations, but it does not disclose new material information that would immediately impact investors.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for reporting purposes and does not contain any new material information or events that would indicate increased risk.

Key Players & Entities

• HOOKIPA Pharma Inc. (company) — Registrant
• January 29, 2025 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.0001 — e on which registered Common Stock, $0.0001 par value per share HOOK The Nasdaq

Filing Documents

• tm254663d1_8k.htm (8-K) — 32KB
• tm254663d1_ex99-1.htm (EX-99.1) — 78KB
• 0001104659-25-007015.txt ( ) — 294KB
• hook-20250129.xsd (EX-101.SCH) — 3KB
• hook-20250129_lab.xml (EX-101.LAB) — 33KB
• hook-20250129_pre.xml (EX-101.PRE) — 22KB
• tm254663d1_8k_htm.xml (XML) — 4KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On December 27, 2024, HOOKIPA Pharma Inc. (the "Company") filed a petition (the "Section 205 Proceeding") in the Delaware Court of Chancery (the "Court of Chancery") pursuant to Section 205 of the Delaware General Corporation Law (the "DGCL") seeking an order validating and declaring effective certain actions taken by the Company's stockholders at the Company's 2022 Annual Meeting of Stockholders (the "2022 Annual Meeting") and 2023 Annual Meeting of Stockholders (the "2023 Annual Meeting"), as described below. The Section 205 Proceeding is captioned In re HOOKIPA Pharma Inc., C.A. No. 2024-1346-KSJM. A copy of the Company's petition filed in the Section 205 Proceeding is attached hereto as Exhibit 99.1 and incorporated herein by reference. At the 2022 Annual Meeting, the Company's stockholders approved, among other things, proposals to (i) elect two Class III directors for three-year terms, (ii) amend the Company's certificate of incorporation to increase the total number of authorized shares of common stock from 100,000,000 shares to 200,000,000 shares, and (iii) amend the Company's 2019 Stock Option and Incentive Plan (collectively, the "2022 Stockholder Actions"). The proposals are described more fully in the Company's definitive proxy statement for the 2022 Annual Meeting, filed with the Securities and Exchange Commission ("SEC") on May 16, 2022, and the voting results from the meeting are set forth in the Company's Current Report on Form 8-K filed with the SEC on July 1, 2022. The record date established for the 2022 Annual Meeting was April 13, 2022, which was 78 days before the date of the 2022 Annual Meeting, which was held on June 30, 2022. Under the DGCL, the record date should have been set for no sooner than Sunday, May 1, 2022, which was the 60th day before the 2022 Annual Meeting. At the 2023 Annual Meeting, the Company's stockholders approved, among other things, a proposal to elect three Class I directors for

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description 99.1 Verified Petition For Relief Under 8 Del. C. 205 of HOOKIPA Pharma Inc., filed December 27, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 29, 2025 HOOKIPA Pharma Inc. By: /s/ Terry Coelho Name: Terry Coelho Title: Executive Vice President and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR